Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)

Phase 2

Completed

• Conditions: Atherosclerosis
• Interventions: Drug: Clopidogrel 75 mg daily; Drug: water pill daily

• Registration Number: NCT00228423
• Lead Sponsor: Ottawa Heart Institute Research Corporation

Brief Summary

The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to aspirin alone.

Detailed Description

Saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery (CABG). The process of saphenous vein intimal hyperplasia is mediated by platelet aggregation and begins just days after surgical revascularization. Subsequently, areas of intimal hyperplasia in turn develop graft atherosclerotic disease and its sequelae. Clopidogrel improves outcomes in patients with atherosclerotic disease, and is effective at reducing intimal hyperplasia in animal models of thrombosis. Therefore, the goal of this study will be to evaluate the efficacy of clopidogrel and aspirin therapy versus aspirin alone in the prevention of saphenous vein graft intimal hyperplasia following one year after CABG.

Patients undergoing multi-vessel CABG and in whom at least two saphenous vein grafts will be used are eligible for the study. Patients will be randomized to receive daily clopidogrel 75 mg or placebo, in addition to daily aspirin 162 mg, for the duration of one year starting as soon as postoperative bleeding has been ruled out on the day of surgery. At the end of one year, all patients will undergo coronary angiography and intravascular ultrasound assessment of one saphenous vein graft as selected by randomization. The study will be powered to test the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20% compared to aspirin alone at one year following bypass surgery.

Study Timeline

• Study First Submitted: 2005-09-26
• Study First Submitted QC: 2005-09-26
• Study First Posted: 2005-09-28
• Study Start: 2006-05
• Primary Completion: 2009-06
• Study Completion: 2009-07
• Status Verified: 2021-03
• Results First Submitted: 2021-03-30
• Results First Submitted QC: 2021-03-30
• Last Update Submitted: 2021-03-30
• Results First Posted: 2021-04-27
• Last Update Posted: 2021-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

• Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.

Read More

Exclusion Criteria

• Emergency surgery
• Valve surgery
• Redo CABG
• Left ventricle ejection fraction < 25%
• Serum creatinine > 130 µmol/L
• Preoperative use of clopidogrel (with the exception of the current admission)
• Preoperative use of warfarin; allergy to aspirin or clopidogrel.
• History of cerebrovascular accident
• History of severe liver disease
• Morbid obesity
• Current malignancy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
75mg Clopidogrel	Clopidogrel 75 mg daily	75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
Placebo	water pill daily	Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.

Primary Outcome Measures

Name	Time	Method
Vein Graft Intimal Area	One year following surgery	IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed

Secondary Outcome Measures

Name	Time	Method
Incidence of Major Adverse Coronary Events Within One Year Following Surgery	1 year
Vein Graft Angiographic Patency	One year following surgery	Postoperative angiogram 12 months post-CABG
Incidence of Major Bleeding Events Within One Year Following Surgery	1 year

Trial Locations

Locations (1)

University of Ottawa Heart Institute; 🇨🇦 Ottawa, Ontario, Canada